Please login to the form below

Not currently logged in
Email:
Password:

Teva's MS drug disappoints in trial

Teva Pharmaceutical Industries has said its oral MS drug laquinimod has failed to reach its primary endpoint in a phase III trial but the company still plans regulatory submissions in the EU and US

Teva Pharmaceutical Industries has said its oral multiple sclerosis (MS) drug laquinimod has failed to reach its primary endpoint in a phase III trial.

Compared to placebo, the therapy, which is being investigated for use in the treatment of relapsing-remitting multiple sclerosis (RRMS), did not reduce annual relapse rates of the disease.

However, Teva said there were dissimilarities in the baseline magnetic resonance imaging (MRI) characteristics of the study group receiving placebo and the study group receiving laquinimod, affecting the trial's results.

When adjusted, laquinimod demonstrated a significant reduction in relapse rate for the disease, as well as a reduced risk of disability progression and brain volume loss.

Teva said additional analyses of the study data are ongoing, and the company still has plans to submit the drug for approval in both the EU and US.

Professor Yitzhak Peterburg, Teva's group vice-president, Global Branded Products, said: "Teva remains committed to the clinical development of laquinimod and is confident that the drug could provide a unique option for the treatment of multiple sclerosis."

2nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics